7-Keto-Dehydroepiandrosterone Acetaldehyde Aldoste

證據等級: L5

預測適應症: 0 個

Multi-Component Hormonal Complex: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This entry contains a complex mixture of 13 substances — including steroid hormones, a catecholamine, gonadotropins, and biological extracts (e.g., Sus scrofa ovary) — with no registered indication in the United States and no DrugBank identifier. The TxGNN model returned no predicted indications for this entry, likely because the compound cannot be mapped to a single node in the knowledge graph. Without a unified drug identity, original indication, or TxGNN output, a standard repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None available
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only; no actual studies linked)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why This Prediction Cannot Be Assessed

The entry submitted to the pipeline contains 13 distinct chemical or biological entities listed as a single INN string:

7-Keto-DHEA · Acetaldehyde · Aldosterone · Androsterone · Cholesterol · Cortisone Acetate · Dopamine Hydrochloride · Estrone · Follitropin · Prasterone (DHEA) · Progesterone · Sus scrofa Ovary Extract · Testosterone

This profile is consistent with a multi-component homeopathic or biological preparation rather than a single molecular entity. TxGNN operates on individual DrugBank nodes; when no DrugBank ID can be assigned, the model has no anchor point in the knowledge graph and cannot generate scored disease predictions.

Additionally, the lack of a defined mechanism of action and the presence of non-pharmacological components (e.g., acetaldehyde as a trace metabolite, Sus scrofa ovary as a biological matrix) further limit computational analysis.

US Market Information

No US NDA, BLA, or homeopathic registration records were retrieved for this entry. The TFDA query (2026-03-24) also returned zero results, confirming no registration in Taiwan.

Safety Considerations

Please refer to the package insert for safety information. No DDI, warning, or contraindication data was available for this entry.

Conclusion and Next Steps

Decision: Hold

Rationale: This entry cannot be evaluated as a single repurposing candidate because it represents a mixture of 13 substances without a unified DrugBank identity, no approved indication, and no TxGNN output. Proceeding without resolving the identity problem would produce meaningless results.

To proceed, the following is needed:

Clarify drug identity: Determine whether this entry represents a single approved product (e.g., a specific homeopathic formulation) or whether each component should be evaluated separately.
Assign DrugBank IDs per component: Each active substance (e.g., Progesterone → DB00396, Testosterone → DB00624, Prasterone → DB01708) should be individually mapped so TxGNN can generate per-component predictions.
Identify the intended original indication: Without a registered use, the repurposing rationale has no baseline to compare against.
Obtain package insert or product monograph: Required to complete the safety screening (DG001 — currently Blocking severity).
Re-run TxGNN per individual component: Once each substance has a valid DrugBank ID, run the pipeline for each separately and aggregate predictions for shared disease targets.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.